Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Cell Biol Int ; 45(5): 1030-1037, 2021 May.
Article in English | MEDLINE | ID: mdl-33404163

ABSTRACT

Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC). Presently, we investigated the regulatory mechanism of Metformin in EOC metastasis. First, Girdin was significantly enhanced in EOC tumorous tissues and cell lines. Seconded, knockdown of Girdin significantly suppressed EOC cell viability, migration, and invasion, while upregulation of Girdin produced the opposite effects in vitro and facilitated lung metastasis in EOC cell xenograft in vivo. In addition, we confirmed that the inhibitory effect of Metformin on Girdin expression. Mechanistically, the oncogenic effects of Girdin could be reversed by LY294002 (an AKT pathway inhibitor) and Metformin. These results suggested that Metformin attenuated EOC metastasis through Girdin and targeting Girdin may be a promising therapeutic strategy for EOC in the future.


Subject(s)
Carcinoma, Ovarian Epithelial/metabolism , Microfilament Proteins/genetics , Neoplasm Metastasis/drug therapy , Vesicular Transport Proteins/genetics , Adult , Animals , Carcinoma, Ovarian Epithelial/genetics , Carcinoma, Ovarian Epithelial/pathology , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Cell Survival/genetics , Epithelial-Mesenchymal Transition , Female , Gene Expression/genetics , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic/genetics , Humans , Metformin/metabolism , Metformin/pharmacology , Mice, Nude , Microfilament Proteins/drug effects , Microfilament Proteins/metabolism , Middle Aged , Neoplasm Invasiveness/genetics , Neoplasm Metastasis/genetics , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Transcriptome/genetics , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism
2.
J Psychiatry Neurosci ; 45(5): 344-355, 2020 09 01.
Article in English | MEDLINE | ID: mdl-32459080

ABSTRACT

Background: Altered function of serotonin receptor 1A (5-HT1AR) has been consistently implicated in anxiety, major depressive disorder and resistance to antidepressants. Mechanisms by which the function of 5-HT1AR (expressed as an autoreceptor in serotonergic raphe neurons and as a heteroreceptor in serotonin [5-HT] projection areas) is altered include regulation of its expression, but 5-HT1AR trafficking may also be involved. Methods: We investigated the consequences of the lack of Yif1B (the 5-HT1AR trafficking protein) on 5-HT neurotransmission in mice, and whether Yif1B expression might be affected under conditions known to alter 5-HT neurotransmission, such as anxious or depressive states or following treatment with fluoxetine (a selective serotonin reuptake inhibitor) in humans, monkeys and mice. Results: Compared with wild-type mice, Yif1B-knockout mice showed a significant decrease in the forebrain density of 5-HT projection fibres and a hypofunctionality of 5-HT1A autoreceptors expressed on raphe 5-HT neurons. In addition, social interaction was less in Yif1B-knockout mice, which did not respond to the antidepressant-like effect of acute fluoxetine injection. In wild-type mice, social defeat was associated with downregulated Yif1B mRNA in the prefrontal cortex, and chronic fluoxetine treatment increased Yif1B expression. The expression of Yif1B was also downregulated in the postmortem prefrontal cortex of people with major depressive disorder and upregulated after chronic treatment with a selective serotonin reuptake inhibitor in monkeys. Limitations: We found sex differences in Yif1B expression in humans and monkeys, but not in mice under the tested conditions. Conclusion: These data support the concept that Yif1B plays a critical role in 5-HT1AR functioning and brain 5-HT homeostasis. The opposite changes in its expression observed in anxious or depressive states and after therapeutic fluoxetine treatment suggest that Yif1B might be involved in vulnerability to anxiety and depression, and fluoxetine efficacy.


Subject(s)
Depressive Disorder, Major/metabolism , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Receptor, Serotonin, 5-HT1A/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin/metabolism , Social Behavior , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism , Animals , Autopsy , Behavior, Animal/physiology , Disease Models, Animal , Female , Fluoxetine/pharmacology , Humans , Macaca mulatta , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Raphe Nuclei/drug effects , Raphe Nuclei/physiology , Serotonergic Neurons/drug effects , Serotonergic Neurons/physiology , Serotonin 5-HT1 Receptor Agonists/pharmacology , Sex Characteristics
3.
J Cell Sci ; 130(14): 2251-2265, 2017 Jul 15.
Article in English | MEDLINE | ID: mdl-28536105

ABSTRACT

Tether complexes play important roles in endocytic and exocytic trafficking of lipids and proteins. In yeast, the multisubunit transport protein particle (TRAPP) tether regulates endoplasmic reticulum (ER)-to-Golgi and intra-Golgi transport and is also implicated in autophagy. In addition, the TRAPP complex acts as a guanine nucleotide exchange factor (GEF) for Ypt1, which is homologous to human Rab1a and Rab1b. Here, we show that human TRAPPC13 and other TRAPP subunits are critically involved in the survival response to several Golgi-disrupting agents. Loss of TRAPPC13 partially preserves the secretory pathway and viability in response to brefeldin A, in a manner that is dependent on ARF1 and the large GEF GBF1, and concomitant with reduced caspase activation and ER stress marker induction. TRAPPC13 depletion reduces Rab1a and Rab1b activity, impairs autophagy and leads to increased infectivity to the pathogenic bacterium Shigella flexneri in response to brefeldin A. Thus, our results lend support for the existence of a mammalian TRAPPIII complex containing TRAPPC13, which is important for autophagic flux under certain stress conditions.


Subject(s)
Antigens, Neoplasm/metabolism , Golgi Apparatus/metabolism , Vesicular Transport Proteins/metabolism , A549 Cells , ADP-Ribosylation Factor 1/metabolism , Anti-Bacterial Agents/pharmacology , Antigens, Neoplasm/drug effects , Autophagy/physiology , Brefeldin A/pharmacology , Dysentery, Bacillary/drug therapy , Dysentery, Bacillary/metabolism , Gene Knockdown Techniques , Guanine Nucleotide Exchange Factors/metabolism , HEK293 Cells , HT29 Cells , HeLa Cells , Humans , Shigella flexneri/drug effects , Vesicular Transport Proteins/antagonists & inhibitors , Vesicular Transport Proteins/drug effects
4.
Cell Metab ; 4(2): 143-54, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16890542

ABSTRACT

Granuphilin is a crucial component of the docking machinery of insulin-containing vesicles to the plasma membrane. Here, we show that the granuphilin promoter is a target of SREBP-1c, a transcription factor that controls fatty acid synthesis, and MafA, a beta cell differentiation factor. Potassium-stimulated insulin secretion (KSIS) was suppressed in islets with adenoviral-mediated overexpression of granuphilin and enhanced in islets with knockdown of granuphilin (in which granuphilin had been knocked down). SREBP-1c and granuphilin were activated in islets from beta cell-specific SREBP-1c transgenic mice, as well as in several diabetic mouse models and normal islets treated with palmitate, accompanied by a corresponding reduction in insulin secretion. Knockdown- or knockout-mediated ablation of granuphilin or SREBP-1c restored KSIS in these islets. Collectively, our data provide evidence that activation of the SREBP-1c/granuphilin pathway is a potential mechanism for impaired insulin secretion in diabetes, contributing to beta cell lipotoxicity.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Insulin/metabolism , Sterol Regulatory Element Binding Protein 1/pharmacology , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/metabolism , Animals , Cells, Cultured , Diabetes Mellitus, Experimental/genetics , Insulin Secretion , Islets of Langerhans/metabolism , Maf Transcription Factors, Large/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, Transgenic , Palmitates/pharmacology , Palmitates/toxicity , Potassium/pharmacology , Promoter Regions, Genetic/drug effects , Signal Transduction , Sterol Regulatory Element Binding Protein 1/metabolism , Vesicular Transport Proteins/drug effects
5.
Eur J Pharmacol ; 873: 172973, 2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32017935

ABSTRACT

Multiple sclerosis (MS) is a neurologic autoimmune disorder featured by chronic inflammation of the central nervous system, demyelination and axonal damage. Recently, the term "oxinflammation" has been proposed to depict the vicious circle of chronic inflammation and oxidative stress (OS). OS promotes demyelination and neurodegeneration directly, by oxidation of lipids, proteins, and DNA but also indirectly, by inducing a dysregulation of the immunity and favoring the state of pro-inflammatory response. Many of the actors of this delicately tuned network are controlled by Keap1/Nrf2/ARE signaling pathway, a principal regulator of antioxidant and phase II detoxification genes. This pathway also has a pivotal role in inflammation, and therefore possesses a great potential in the treatment of MS. The aim of this review is to provide the newest insights in the preclinical and clinical evidence of Nrf2 induction in the regeneration of the antioxidant response and attenuation of inflammation in MS. Preclinical studies have indicated that activators of this pathway, such as epigallocatechin gallate (EGCG), curcumin, melatonin, resveratrol, and sulforaphane might be a promising therapeutic option in amelioration of MS symptoms, nevertheless, the efficacy and safety of these compounds have to be confirmed in future clinical trials.


Subject(s)
Kelch-Like ECH-Associated Protein 1/drug effects , Multiple Sclerosis/drug therapy , NF-E2-Related Factor 2/drug effects , Signal Transduction/drug effects , Vesicular Transport Proteins/drug effects , Animals , Humans
6.
Nat Cell Biol ; 22(1): 74-86, 2020 01.
Article in English | MEDLINE | ID: mdl-31907414

ABSTRACT

Collagen is the most abundant secreted protein in vertebrates and persists throughout life without renewal. The permanency of collagen networks contrasts with both the continued synthesis of collagen throughout adulthood and the conventional transcriptional/translational homeostatic mechanisms that replace damaged proteins with new copies. Here, we show circadian clock regulation of endoplasmic reticulum-to-plasma membrane procollagen transport by the sequential rhythmic expression of SEC61, TANGO1, PDE4D and VPS33B. The result is nocturnal procollagen synthesis and daytime collagen fibril assembly in mice. Rhythmic collagen degradation by CTSK maintains collagen homeostasis. This circadian cycle of collagen synthesis and degradation affects a pool of newly synthesized collagen, while maintaining the persistent collagen network. Disabling the circadian clock causes abnormal collagen fibrils and collagen accumulation, which are reduced in vitro by the NR1D1 and CRY1/2 agonists SR9009 and KL001, respectively. In conclusion, our study has identified a circadian clock mechanism of protein homeostasis wherein a sacrificial pool of collagen maintains tissue function.


Subject(s)
Circadian Clocks/physiology , Collagen/metabolism , Homeostasis/physiology , Secretory Pathway/physiology , Animals , Aryl Hydrocarbon Receptor Nuclear Translocator/drug effects , Aryl Hydrocarbon Receptor Nuclear Translocator/metabolism , Carbazoles/pharmacology , Collagen/drug effects , Cyclic Nucleotide Phosphodiesterases, Type 4/drug effects , Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism , Extracellular Matrix/metabolism , Mice, Transgenic , Pyrrolidines/pharmacology , SEC Translocation Channels/drug effects , SEC Translocation Channels/metabolism , Secretory Pathway/genetics , Sulfonamides/pharmacology , Thiophenes/pharmacology , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism
7.
Toxicology ; 442: 152537, 2020 09.
Article in English | MEDLINE | ID: mdl-32663520

ABSTRACT

Long-term exposure to isoflurane may induce long-term developmental neurotoxicity and cognitive impairments in the neonatal brains. Trilobatin, a leaf extract from the Chinese traditional sweet tea Lithocarpus polystachyus Rehd, possesses various biological properties including anti-inflammatory and anti-oxidant properties. Our study aimed to explore the neuroprotective effect of trilobatin on isoflurane-induced neurotoxicity in mouse hippocampal neuronal HT22 cells. The effects of trilobatin on cell viability, LDH release, apoptosis, and caspase-3/7 activity in isoflurane-induced HT22 cells were explored by CCK-8, LDH release assay, flow cytometry analysis, and caspase-3/7 activity assay, respectively. Oxidative stress was evaluated by measuring the levels of reactive oxygen species (ROS) and malonyldialdehyde (MDA) and activities of superoxide dismutase (SOD) and catalase (CAT). The expression of nuclear erythroid-2 related factor 2 (Nrf2), nuclear Nrf2, heme oxygenase-1 (HO-1), and NAD(P)H: quinone oxidoreductase 1 (NQO1) was determined by western blot and qRT-PCR. Results suggested that exposure to isoflurane significantly reduced cell viability and increased LDH release, apoptotic rate and caspase-3/7 activity in HT22 cells, which were abolished by trilobatin. Trilobatin reversed isoflurane-induced increase of ROS and MDA levels and reduction of SOD and CAT activities in HT22 cells. Additionally, trilobatin promoted the nuclear translocation of Nrf2 as well as the mRNA and protein expression of HO-1 and NQO1 in HT22 cells exposed to isoflurane. Nrf2 knockdown attenuated the effects of trilobatin on isoflurane-induced viability reduction, LDH release, apoptosis, and oxidative stress in HT22 cells. Overall, trilobatin protected HT22 cells against isoflurane-induced neurotoxicity via activating the Nrf2/antioxidant response element (ARE) pathway.


Subject(s)
Anesthetics, Inhalation/toxicity , Flavonoids/pharmacology , Isoflurane/antagonists & inhibitors , Isoflurane/toxicity , Major Histocompatibility Complex/drug effects , NF-E2-Related Factor 2/drug effects , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Polyphenols/pharmacology , Signal Transduction/drug effects , Vesicular Transport Proteins/drug effects , Animals , Apoptosis/drug effects , Cell Line , Cell Survival/drug effects , Hippocampus/drug effects , Mice , Plant Extracts/pharmacology , Reactive Oxygen Species/metabolism
8.
Neurochem Int ; 52(6): 979-89, 2008 May.
Article in English | MEDLINE | ID: mdl-18037536

ABSTRACT

The effect of alpha-tocopherol, the major vitamin E component, on the release of endogenous glutamate has been investigated using rat cerebrocortical nerve terminals. Results showed that alpha-tocopherol facilitated the Ca2+-dependent but not the Ca2+-independent glutamate release evoked by 4-aminopyridine (4AP). This release facilitation was insensitive to glutamate transporter inhibitor L-trans-PDC or DL-TBOA, and blocked by the exocytotic neurotransmitter release inhibitor tetanus neurotoxin, indicating that alpha-tocopherol affects specifically the physiological exocytotic vesicular release without affecting the non-vesicular release. Facilitation of glutamate exocytosis by alpha-tocopherol was not due to its increasing synaptosomal excitability, because alpha-tocopherol did not alter the 4AP-evoked depolarization of the synaptosomal plasma membrane potential. Rather, examination of the effect of alpha-tocopherol on cytoplasmic free Ca2+ concentration revealed that the facilitation of glutamate release could be attributed to an increase in voltage-dependent Ca2+ influx. Consistent with this, the alpha-tocopherol-mediated facilitation of glutamate release was significantly reduced in synaptosomes pretreated with omega-CgTX MVIIC, a wide spectrum blocker of N- and P/Q-type Ca2+ channels. In addition, alpha-tocopherol modulation of glutamate release appeared to involve a protein kinase C (PKC) signalling cascade, insofar as pretreatment of synaptosomes with the PKC inhibitor GF109203X effectively suppressed the facilitatory effect of alpha-tocopherol on 4AP- or ionomycin-evoked glutamate release. Furthermore, alpha-tocopherol increased the phosphorylation of MARCKS, the major presynapic substrate for PKC, and this effect was also significantly attenuated by PKC inhibition. Together, these results suggest that alpha-tocopherol exerts an increase in PKC activation, which subsequently enhances voltage-dependent Ca2+ influx and vesicular release machinery to cause an increase in evoked glutamate release from rat cerebrocortical glutamatergic terminals. This finding might provide important information regarding to the action of vitamin E in the central nervous system.


Subject(s)
Cerebral Cortex/metabolism , Exocytosis/physiology , Glutamic Acid/metabolism , Presynaptic Terminals/metabolism , alpha-Tocopherol/metabolism , 4-Aminopyridine/pharmacology , Animals , Calcium Channels/drug effects , Calcium Channels/metabolism , Calcium Signaling/drug effects , Calcium Signaling/physiology , Cerebral Cortex/drug effects , Enzyme Activation/drug effects , Enzyme Activation/physiology , Exocytosis/drug effects , Intracellular Signaling Peptides and Proteins/drug effects , Intracellular Signaling Peptides and Proteins/metabolism , Male , Membrane Proteins/drug effects , Membrane Proteins/metabolism , Metalloendopeptidases/pharmacology , Myristoylated Alanine-Rich C Kinase Substrate , Potassium Channel Blockers/pharmacology , Presynaptic Terminals/drug effects , Protein Kinase C/drug effects , Protein Kinase C/metabolism , Rats , Rats, Sprague-Dawley , Synaptic Membranes/drug effects , Synaptic Membranes/metabolism , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Synaptosomes , Tetanus Toxin/pharmacology , Vesicular Glutamate Transport Proteins/antagonists & inhibitors , Vesicular Glutamate Transport Proteins/metabolism , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism , alpha-Tocopherol/pharmacology
9.
Lipids ; 43(10): 913-23, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18769950

ABSTRACT

Synthetic activators of peroxisome proliferator-activated receptors (PPAR)-alpha and -gamma are capable of reducing macrophage foam cell cholesterol accumulation through the activation of genes involved in cholesterol homeostasis. Since conjugated linoleic acids (CLA) were also demonstrated to activate PPARalpha and PPARgamma in vivo and in vitro, we tested the hypothesis that CLA are also capable of reducing macrophage foam cell cholesterol accumulation. Thus, mouse RAW264.7 macrophage-derived foam cells were treated with CLA isomers, c9t11-CLA and t10c12-CLA, and linoleic acid (LA), as reference fatty acid, and analyzed for the concentrations of free and esterified cholesterol, cholesterol efflux and expression of genes involved in cholesterol homeostasis (CD36, ABCA1, LXRalpha, NPC-1, and NPC-2). Treatment with c9t11-CLA and t10c12-CLA, but not LA, lowered cholesterol accumulation, stimulated acceptor-dependent cholesterol efflux, and increased relative mRNA concentrations of CD36, ABCA1, LXRalpha, NPC-1, and NPC-2 (P < 0.05). In conclusion, the present study showed that CLA isomers reduce cholesterol accumulation in RAW264.7 macrophage-derived foam cells presumably by enhancing lipid acceptor-dependent cholesterol efflux.


Subject(s)
Cholesterol/metabolism , Foam Cells/metabolism , Linoleic Acids, Conjugated/metabolism , PPAR gamma/metabolism , ATP Binding Cassette Transporter 1 , ATP-Binding Cassette Transporters/drug effects , ATP-Binding Cassette Transporters/metabolism , Animals , CD36 Antigens/drug effects , CD36 Antigens/metabolism , Cell Line , Cell Survival/drug effects , DNA-Binding Proteins/drug effects , DNA-Binding Proteins/metabolism , Foam Cells/drug effects , Humans , Intracellular Signaling Peptides and Proteins , Isomerism , Linoleic Acids, Conjugated/pharmacology , Liver X Receptors , Mice , Niemann-Pick C1 Protein , Orphan Nuclear Receptors , PPAR gamma/drug effects , Proteins/drug effects , Proteins/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Receptors, Cytoplasmic and Nuclear/drug effects , Receptors, Cytoplasmic and Nuclear/metabolism , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism
10.
BMC Neurosci ; 8: 67, 2007 Aug 16.
Article in English | MEDLINE | ID: mdl-17705834

ABSTRACT

BACKGROUND: Many studies have shown that mitochondrial dysfunction, complex I inhibition in particular, is involved in the pathogenesis of Parkinson's disease (PD). Rotenone, a specific inhibitor of mitochondrial complex I, has been shown to produce neurodegeneration in rats as well as in many cellular models that closely resemble PD. However, the mechanisms through which complex I dysfunction might produce neurotoxicity are as yet unknown. A comprehensive analysis of the mitochondrial protein expression profile affected by rotenone can provide important insight into the role of mitochondrial dysfunction in PD. RESULTS: Here, we present our findings using a recently developed proteomic technology called SILAC (stable isotope labeling by amino acids in cell culture) combined with polyacrylamide gel electrophoresis and liquid chromatography-tandem mass spectrometry to compare the mitochondrial protein profiles of MES cells (a dopaminergic cell line) exposed to rotenone versus control. We identified 1722 proteins, 950 of which are already designated as mitochondrial proteins based on database search. Among these 950 mitochondrial proteins, 110 displayed significant changes in relative abundance after rotenone treatment. Five of these selected proteins were further validated for their cellular location and/or treatment effect of rotenone. Among them, two were confirmed by confocal microscopy for mitochondrial localization and three were confirmed by Western blotting (WB) for their regulation by rotenone. CONCLUSION: Our findings represent the first report of these mitochondrial proteins affected by rotenone; further characterization of these proteins may shed more light on PD pathogenesis.


Subject(s)
Dopamine/metabolism , Mitochondria/drug effects , Mitochondrial Proteins/drug effects , Neurons/drug effects , Rotenone/toxicity , Uncoupling Agents/toxicity , Cell Line , Electron Transport Complex I/drug effects , Electron Transport Complex I/metabolism , Electrophoresis, Polyacrylamide Gel , Heat-Shock Proteins/drug effects , Heat-Shock Proteins/metabolism , Humans , Immunohistochemistry , Mitochondria/metabolism , Mitochondrial Proteins/analysis , Mitochondrial Proteins/metabolism , Neurons/metabolism , Proteomics/methods , Sorting Nexins , Vesicle-Associated Membrane Protein 3/drug effects , Vesicle-Associated Membrane Protein 3/metabolism , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism
11.
Clin Cancer Res ; 12(23): 6952-9, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17145813

ABSTRACT

PURPOSE: Colon cancer is one of the most common human malignancies, yet studies have only begun to identify the multiple mechanisms that underlie the development of this tumor. In this study, we have identified a novel mechanism, dysregulation of endocytic sorting, which promotes colon cancer development. EXPERIMENTAL DESIGN: Immunohistochemical and microarray analyses were done on human colon cancer tissue specimens to determine the levels of one endocytic protein, sorting nexin 1 (SNX1). SW480 cells, a human colon cancer cell line that retains a relatively high level of SNX1 expression, were used to assess the effects of down-regulating this protein by small hairpin RNA. Activation of signal transduction cascades was evaluated in these cells using Western blotting, and multiple functional assays were done. RESULTS: We determined by immunohistochemistry that the level of SNX1 was significantly down-regulated in 75% of human colon cancers. In corroborative studies using microarray analysis, SNX1 message was significantly decreased (log(2) ratio less than -1) for 8 of 19 colon carcinomas. Cell lines with reduced SNX1 levels showed increased proliferation, decreased apoptosis, and decreased susceptibility to anoikis. They also showed increased activation of epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 in response to epidermal growth factor. This increased activation was abolished by inhibition of endocytosis. CONCLUSIONS: These data suggest that loss of SNX1 may play a significant role in the development and aggressiveness of human colon cancer, at least partially through the mechanism of increased signaling from endosomes. Further, these findings suggest that dysregulation of endocytic proteins may represent a new paradigm in the process of carcinogenesis.


Subject(s)
Colonic Neoplasms/genetics , Down-Regulation/genetics , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/metabolism , Apoptosis , Cell Line, Tumor , Cell Proliferation , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Disease Progression , Down-Regulation/drug effects , ErbB Receptors/drug effects , ErbB Receptors/metabolism , Gene Expression Regulation, Neoplastic/genetics , Humans , Immunohistochemistry , Mitogen-Activated Protein Kinase 1/drug effects , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/drug effects , Mitogen-Activated Protein Kinase 3/metabolism , Oligonucleotide Array Sequence Analysis/methods , Phosphorylation , RNA, Small Interfering/pharmacology , Signal Transduction/drug effects , Sorting Nexins , Structure-Activity Relationship , Vesicular Transport Proteins/drug effects
12.
Trends Mol Med ; 11(8): 377-81, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16006188

ABSTRACT

Botulinum neurotoxin serotype A (BoNT/A) has achieved a dichotomous status in modern medicine; it is both a versatile treatment for several neurological disorders and a lethal poison responsible for causing the neuroparalytic syndrome botulism. The extent of paralysis largely depends on the dosage of toxin received. The toxins block neurotransmitter release by delivering their Zn(2+)-dependent protease components to the presynaptic side of chemical synapses. These highly specialized enzymes exclusively hydrolyze peptide bonds within SNARE (soluble N-ethylmaleiamide-sensitive factor attachment protein receptor) proteins. Recently, the structural basis for the highly specific interaction between BoNT/A and its target SNARE, SNAP-25 (synaptosomal-associated protein of 25kDa), was elucidated. New details regarding the nature of the toxin-SNARE interactions could be exploited for novel inhibitor design.


Subject(s)
Botulinum Toxins, Type A/pharmacology , Neuromuscular Agents/pharmacology , Neurotransmitter Agents/antagonists & inhibitors , Vesicular Transport Proteins/drug effects , Botulinum Toxins, Type A/chemistry , SNARE Proteins , Vesicular Transport Proteins/chemistry
13.
Semin Nephrol ; 25(5): 322-7, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16139687

ABSTRACT

In the current report we review the results that lay grounds for the model of intracellular sodium-mediated dopamine-induced endocytosis of Na,K-ATPase. Under conditions of a high salt diet, dopamine activates PKCzeta, which phosphorylates NKA alpha1 Ser-18. The phosphorylation produces a conformational change of alpha1 NH2-terminus, which through interaction with other domains of alpha1 exposes PI3K- and AP-2-binding domains. PI3K bound to the NKA alpha1 induces the recruitment and activation of other proteins involved in endocytosis, and PI3K-generated 3-phosphoinositides affect the local cytoskeleton and modify the biophysical conditions of the membrane for development of clathrin-coated pits. Plasma membrane phosphorylated NKA is internalized to specialized intracellular compartments where the NKA will be dephosphorylated. The NKA internalization results in a reduced Na+ transport by proximal tubule epithelial cells.


Subject(s)
Cardiotonic Agents/pharmacology , Dopamine/pharmacology , Epithelial Cells/drug effects , Epithelial Cells/enzymology , Kidney Tubules, Proximal/cytology , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Sodium-Potassium-Exchanging ATPase/drug effects , Animals , Blood Pressure/drug effects , Endocytosis/drug effects , Humans , Multiprotein Complexes/drug effects , Multiprotein Complexes/metabolism , Phosphorylation/drug effects , Protein Kinase C/drug effects , Protein Kinase C/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism
14.
Brain Res Mol Brain Res ; 137(1-2): 23-30, 2005 Jun 13.
Article in English | MEDLINE | ID: mdl-15950757

ABSTRACT

Defective heme synthesis may cause acute porphyrias, which are associated with a wide array of neurological disturbances involving both the central and peripheral nervous systems. Thus, the understanding of the roles of heme in neuronal cell function may provide insights into the molecular events underlying the pathogenesis of neuropathies associated with defective heme synthesis. In this report, we use rat pheochromocytoma (PC12) clonal cells as a model system for studying the role of heme in neuronal cell survival. We examined the effects of inhibition of heme synthesis on signaling pathways and gene expression in nerve growth factor (NGF)-induced PC12 cells. We found that succinyl acetone-induced heme deficiency selectively caused apoptosis in NGF-induced PC12 cells. Further, we found that in succinyl acetone-treated, NGF-induced cells, the pro-survival Ras-ERK1/2 signaling pathway was inactivated and the pro-apoptotic JNK signaling pathway was activated. In these cells, the activation of caspase and the cleavage of nuclear poly (ADP-ribose) polymerase (PARP) were also evident. Importantly, microarray gene expression analysis showed that more than 20 key neuronal genes that were induced by NGF were suppressed by succinyl acetone. These genes include those encoding survival motor neuron protein, synaptic vesicle protein SVOP, and neural cell adhesion molecule NCAM. These results indicate that heme is important for neuronal cell signaling and the proper functioning of neuronal cells.


Subject(s)
Apoptosis/genetics , Gene Expression Regulation, Enzymologic/genetics , Heme/deficiency , Nerve Degeneration/genetics , Neurons/metabolism , Porphyrias/complications , Animals , Apoptosis/drug effects , Caspases/drug effects , Caspases/metabolism , Cell Survival/drug effects , Cell Survival/genetics , Collagen Type XI/drug effects , Collagen Type XI/metabolism , Cyclic AMP Response Element-Binding Protein/drug effects , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Down-Regulation/drug effects , Down-Regulation/physiology , Enzyme Inhibitors , Gene Expression Regulation, Enzymologic/drug effects , Heme/biosynthesis , Heptanoates , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Membrane Proteins/drug effects , Membrane Proteins/genetics , Membrane Proteins/metabolism , Nerve Degeneration/metabolism , Nerve Degeneration/physiopathology , Nerve Tissue Proteins/drug effects , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neural Cell Adhesion Molecules/drug effects , Neural Cell Adhesion Molecules/genetics , Neural Cell Adhesion Molecules/metabolism , Neurons/drug effects , Neurons/pathology , PC12 Cells , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases , Porphyrias/metabolism , Porphyrias/physiopathology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , RNA-Binding Proteins/drug effects , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Rats , SMN Complex Proteins , Up-Regulation/drug effects , Up-Regulation/physiology , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/metabolism
15.
Arthritis Rheumatol ; 67(9): 2447-56, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26016600

ABSTRACT

OBJECTIVE: Giant cell arteritis (GCA) is pathologically characterized by dysfunctional angiogenesis and inflammatory cell infiltration. Acute-phase serum amyloid A (A-SAA) is an acute-phase reactant, but is also produced at sites of inflammation and may contribute to vascular inflammation in atherosclerosis. This study was undertaken to examine the effect of A-SAA on proinflammatory pathways and angiogenesis in GCA, using a novel ex vivo temporal artery tissue explant model. METHODS: Serum A-SAA levels were measured by enzyme-linked immunosorbent assay (ELISA). Temporal artery explants and peripheral blood mononuclear cell (PBMC) cultures were established from patients with GCA. Temporal artery explant morphology, viability, and spontaneous release of proinflammatory mediators following 24-hour culture were assessed by hematoxylin and eosin, calcein viability staining, and ELISA. Temporal artery explants and PBMC cultures were stimulated with A-SAA (10 µg/ml), and interleukin-6 (IL-6), IL-8, vascular endothelial growth factor, Ang2, and matrix metalloproteinase 2 (MMP-2)/MMP-9 were quantified by ELISA and gelatin zymography. The effect of conditioned medium from temporal artery explants on angiogenesis was assessed using endothelial cell Matrigel tube-formation assays. Temporal artery explants were also embedded in Matrigel, and myofibroblast outgrowth was assessed. RESULTS: Serum A-SAA levels were significantly higher in GCA patients versus healthy controls (P < 0.0001). Intact tissue morphology, cell viability, and spontaneous cytokine secretion were demonstrated in temporal artery explants. A-SAA treatment induced a significant increase in the levels of IL-6 and IL-8 from temporal artery explants (P < 0.05) and IL-8 from PBMCs (P < 0.05) compared to basal conditions. Conditioned medium from A-SAA-treated explants significantly induced angiogenic tube formation (P < 0.05 versus basal controls). Finally, A-SAA induced myofibroblast outgrowth and MMP-9 activation. CONCLUSION: Our findings demonstrate a functional role for A-SAA in regulating temporal artery inflammation, angiogenesis, and invasion, all key processes in the pathogenesis of GCA.


Subject(s)
Giant Cell Arteritis/immunology , Myofibroblasts/drug effects , Neovascularization, Pathologic/immunology , Serum Amyloid A Protein/pharmacology , Temporal Arteries/drug effects , Acute-Phase Proteins/immunology , Acute-Phase Proteins/pharmacology , Aged , Aged, 80 and over , Cells, Cultured , Female , Giant Cell Arteritis/metabolism , Humans , In Vitro Techniques , Inflammation/immunology , Interleukin-6/immunology , Interleukin-8/drug effects , Interleukin-8/immunology , Leukocytes, Mononuclear , Male , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/immunology , Matrix Metalloproteinase 9/drug effects , Matrix Metalloproteinase 9/immunology , Middle Aged , Serum Amyloid A Protein/immunology , Temporal Arteries/immunology , Vascular Endothelial Growth Factor A/drug effects , Vascular Endothelial Growth Factor A/immunology , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/immunology
16.
An Bras Dermatol ; 89(6): 891-7, 2014.
Article in English | MEDLINE | ID: mdl-25387493

ABSTRACT

BACKGROUND: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis. OBJECTIVE: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent. METHODS: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers. RESULTS: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin. CONCLUSION: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/analysis , Lymphatic Vessels/pathology , Psoriasis/drug therapy , Tumor Necrosis Factor Inhibitors , Vascular Endothelial Growth Factors/analysis , Vesicular Transport Proteins/analysis , Adult , Antibodies, Monoclonal, Murine-Derived/drug effects , Biomarkers/analysis , Biopsy , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Immunohistochemistry , Immunologic Factors/therapeutic use , Lymphangiogenesis/drug effects , Lymphatic Vessels/drug effects , Male , Middle Aged , Psoriasis/metabolism , Psoriasis/pathology , Receptors, Tumor Necrosis Factor/therapeutic use , Reference Values , Skin/drug effects , Skin/pathology , Statistics, Nonparametric , Vascular Endothelial Growth Factors/drug effects , Vesicular Transport Proteins/drug effects
17.
Salud colect ; 11(1): 99-114, ene.-mar. 2015. ilus, tab
Article in Spanish | LILACS | ID: lil-746687

ABSTRACT

El Consejo Federal de Medicina de Brasil (CFM) -órgano normativo y fiscalizador del ejercicio ético de la medicina- prohibió, en 2008, la participación de médicos brasileños en investigaciones que utilizaran placebo para enfermedades con tratamiento eficaz y efectivo, en contraposición a la Declaración de Helsinki, que permite su uso en condiciones metodológicamente justificadas. Con el objetivo de verificar si la normativa ética del CFM modificó el uso de placebo en ensayos clínicos de fase III en Brasil, se analizaron varias características de sus registros en el ClinicalTrials.gov, en los períodos de 2003 a 2007 y de 2009 a 2013. Se concluye que: a) la normativa promulgada por el CFM en 2008 fue ineficaz y prevaleció la posición adoptada por la Declaración de Helsinki; b) el patrocinio de ensayos con placebo por parte de la industria farmacéutica multinacional fue significativo; c) predominaron las investigaciones de fármacos para enfermedades crónicas, y fueron poco significativas para las enfermedades postergadas, de importancia para Brasil.


In 2008, Brazil's Federal Council of Medicine [Conselho Federal de Medicina] (CFM) - regulatory and supervisory agency on the ethical practice of medicine - banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMF's ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.gov were researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.


Subject(s)
Animals , Rats , Apoptosis/genetics , Gene Expression Regulation, Enzymologic/genetics , Heme/deficiency , Nerve Degeneration/genetics , Neurons/metabolism , Porphyrias/complications , Apoptosis/drug effects , Caspases/drug effects , Caspases/metabolism , Cell Survival/drug effects , Cell Survival/genetics , Collagen Type XI/drug effects , Collagen Type XI/metabolism , Cyclic AMP Response Element-Binding Protein/drug effects , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Down-Regulation/drug effects , Down-Regulation/physiology , Enzyme Inhibitors , Gene Expression Regulation, Enzymologic/drug effects , Heme/biosynthesis , Heptanoates , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Membrane Proteins/drug effects , Membrane Proteins/genetics , Membrane Proteins/metabolism , Nerve Degeneration/metabolism , Nerve Degeneration/physiopathology , Nerve Tissue Proteins/drug effects , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neural Cell Adhesion Molecules/drug effects , Neural Cell Adhesion Molecules/genetics , Neural Cell Adhesion Molecules/metabolism , Neurons/drug effects , Neurons/pathology , Poly(ADP-ribose) Polymerases , Porphyrias/metabolism , Porphyrias/physiopathology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , RNA-Binding Proteins/drug effects , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , SMN Complex Proteins , Up-Regulation/drug effects , Up-Regulation/physiology , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/metabolism
18.
An. bras. dermatol ; 89(6): 891-897, Nov-Dec/2014. tab, graf
Article in English | LILACS | ID: lil-727638

ABSTRACT

BACKGROUND: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis. OBJECTIVE: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent. METHODS: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers. RESULTS: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin. CONCLUSION: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antibodies, Monoclonal, Murine-Derived/analysis , Lymphatic Vessels/pathology , Psoriasis/drug therapy , Tumor Necrosis Factors/antagonists & inhibitors , Vascular Endothelial Growth Factors/analysis , Vesicular Transport Proteins/analysis , Antibodies, Monoclonal, Murine-Derived/drug effects , Biopsy , Biomarkers/analysis , Immunohistochemistry , Immunoglobulin G/therapeutic use , Immunologic Factors/therapeutic use , Lymphangiogenesis/drug effects , Lymphatic Vessels/drug effects , Psoriasis/metabolism , Psoriasis/pathology , Reference Values , Receptors, Tumor Necrosis Factor/therapeutic use , Statistics, Nonparametric , Skin/drug effects , Skin/pathology , Vascular Endothelial Growth Factors/drug effects , Vesicular Transport Proteins/drug effects
19.
ACS Chem Biol ; 3(12): 745-7, 2008 Dec 19.
Article in English | MEDLINE | ID: mdl-19099395

ABSTRACT

HIV-1 release requires a direct interaction between the p6 domain of the Gag protein and Tsg101, a component of the cellular endosomal sorting complex required for transport I (ESCRT-I). Disruption of the binding between Gag and Tsg101 is highly detrimental to particle release, making this viral-host cell interaction a potential target for the development of novel anti-HIV-1 agents. An article in this issue reports on the application of a bacterial reverse two-hybrid strategy to identify a cyclic peptide that disrupts Gag-Tsg101 binding and suppresses HIV-1 particle release.


Subject(s)
DNA-Binding Proteins/antagonists & inhibitors , HIV-1/drug effects , HIV-1/physiology , Peptides, Cyclic/pharmacology , Transcription Factors/antagonists & inhibitors , gag Gene Products, Human Immunodeficiency Virus/antagonists & inhibitors , DNA-Binding Proteins/metabolism , Endosomal Sorting Complexes Required for Transport , Endosomes/metabolism , Humans , Models, Biological , Protein Binding/drug effects , Transcription Factors/metabolism , Vesicular Transport Proteins/drug effects , Vesicular Transport Proteins/metabolism , gag Gene Products, Human Immunodeficiency Virus/metabolism
20.
Traffic ; 6(5): 366-73, 2005 May.
Article in English | MEDLINE | ID: mdl-15813747

ABSTRACT

Intracellular membrane trafficking in eukaryotes involves the budding of vesicles from a donor compartment, their translocation, and subsequent fusion with a target membrane. This last step has been shown to involve SNARE proteins, classified into two categories, vesicular (v)-SNAREs and target (t)-SNAREs. It is the pairing of v- and t-SNAREs that is responsible for bringing the lipid bilayers together for membrane fusion. Key to the discovery of SNAREs is the sensitivity of their neuronal synaptic prototypes, which mediate the release of neurotransmitters, to clostridial neurotoxins. In this review, we focus on tetanus neurotoxin-sensitive and tetanus neurotoxin-insensitive v-SNAREs, in particular synaptobrevin and cellubrevin, both tetanus neurotoxin-sensitive and Tetanus neurotoxin-Insensitive Vesicle-Associated Membrane Protein (TI-VAMP, also called VAMP7). The brevins are characterized by an RD sequence in the middle of their SNARE motif whereas TI-VAMP has an RG sequence. These two categories of exocytic v-SNAREs define two important routes to and from the plasma membrane: one sensitive, the other insensitive to tetanus neurotoxin. We also discuss the central role of the endosomal system that could be considered, as already suggested for Rab proteins, as a mosaic of v-SNAREs, thus raising the question of whether or not these two routes can merge, and if so, how and where.


Subject(s)
Cell Membrane/metabolism , Membrane Proteins/metabolism , Metalloendopeptidases/pharmacology , Tetanus Toxin/pharmacology , Vesicular Transport Proteins/metabolism , Animals , Endosomes/metabolism , Exocytosis , Humans , Lipid Bilayers/chemistry , Membrane Fusion , Membrane Proteins/chemistry , Models, Biological , R-SNARE Proteins , SNARE Proteins , Signal Transduction , Synaptic Vesicles/chemistry , Vesicle-Associated Membrane Protein 3 , Vesicular Transport Proteins/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL